Piper Sandler raised the firm’s price target on Abivax (ABVX) to $112 from $70 and keeps an Overweight rating on the shares. After fully digesting obefazimod Phase 3 induction data in ulcerative colitis, the firm thinks it’s appropriate to layer in revenue in early-line UC, and doing so essentially doubles its U.S. UC revenue estimate to EUR 2,656M in 2035. Thus, Piper still believes there’s significant upside that can make its way into the stock heading into key data events.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax SA Announces $608.6 Million Public Offering of ADSs
- Abivax prices 10.2M ADSs at $64.00 in underwritten public offering
- Abivax 10.16M ADS offering priced at $64.00
- Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
- Abivax announces trading resumption of shares on Euronext Paris